The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Tyvaso
treprostinil · TREPROSTINIL 1.74 mg/2.9mL · Inhalant · Oral · United Therapeutics Corporation
NDC 66302-0206-01 · 1 BOX in 1 KIT / 28 AMPULE in 1 BOX / 2.9 mL in 1 AMPULE · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$832.83per billing unit (1.74 MG)HCPCS J7686 · Jul 1, 2026
- Part D plans paid (avg)$200.41per dosage unitgross, before rebates — matched by drug name · 2024
- Federal ceiling (Big4)$17,613.64per unitUnited Therapeutics Corporation · Jan 1, 2026
- List price (WAC, as filed)$26,155.15per packageUnited Therapeutics · Jan 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$26,115.15
Reported to Texas DSHS · 2026 annual filing · United Therapeutics Corporation
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1.74 MG
$832.827
HCPCS J7686 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2024)
$303,319
13 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- United Therapeutics CorporationUnited Stateslabel · manufacture · pack
- United Therapeutics CorporationUnited Statesanalysis · api manufacture · label · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $24,031.41 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA022387
- TE code
- —
- Approval date
- Jul 30, 2009
- Patents / exclusivity
- 6 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 11826327 | Feb 3, 2042 |
| patent | 9593066 | Dec 15, 2028 |
| patent | 11723887 | Dec 15, 2028 |
| patent | 9358240 | May 5, 2028 |
| patent | 9339507 | Mar 10, 2028 |
| patent | 10376525 | May 14, 2027 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class III · TerminatedAug 14, 2018United Therapeutics Corp. — Defective Delivery System: Water ingress through the lower water cup sensor of the device.
Manufacturers of treprostinil (Inhalant)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| United Therapeutics Corporation | TREPROSTINIL 32 ug/1 | Jul 15, 2026 | Sep 3, 2026 |
| United Therapeutics Corporation | TREPROSTINIL 64 ug/1 | Jul 15, 2026 | Sep 3, 2026 |
| United Therapeutics Corporation | TREPROSTINIL 80 ug/1 | Jul 15, 2026 | Sep 3, 2026 |
| United Therapeutics Corporation | TREPROSTINIL 1.74 mg/2.9mL | Jul 15, 2026 | Sep 2, 2026 |
| United Therapeutics Corporation | TREPROSTINIL 16 ug/1 | Jul 15, 2026 | Aug 31, 2026 |
| United Therapeutics Corporation | TREPROSTINIL 48 ug/1 | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Tyvaso — NDC 66302-0206-01," retrieved September 3, 2026, https://drugdashboards.com/drug/66302020601.
Free to cite with attribution — see how the data is put together.